The invention relates to the use a substance signaling through gp130 for the manufacture of a medicament for the treatment and/or prevention of diabetic neuropathy. The use of IL-6 is preferred.

 
Web www.patentalert.com

< 3-aminopiperidines and 3-aminoquinuclidines as inhibitors of monoamine uptake

> Fc-erythropoietin fusion protein with improved pharmacokinetics
~ 00484